OXB vs. BVXP, HVO, AVCT, 4BB, FARN, FUM, SCLP, PRTC, ONT, and NIOX
Should you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Bioventix (BVXP), hVIVO (HVO), Avacta Group (AVCT), 4basebio (4BB), Faron Pharmaceuticals Oy (FARN), Futura Medical (FUM), Scancell (SCLP), PureTech Health (PRTC), Oxford Nanopore Technologies (ONT), and NIOX Group (NIOX). These companies are all part of the "medical" sector.
Bioventix (LON:BVXP) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.
In the previous week, Bioventix had 3 more articles in the media than Oxford Biomedica. MarketBeat recorded 3 mentions for Bioventix and 0 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.20 beat Bioventix's score of 0.00 indicating that Bioventix is being referred to more favorably in the media.
Bioventix has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
Oxford Biomedica received 266 more outperform votes than Bioventix when rated by MarketBeat users. Likewise, 66.79% of users gave Oxford Biomedica an outperform vote while only 52.87% of users gave Bioventix an outperform vote.
Bioventix has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.
62.9% of Bioventix shares are held by institutional investors. Comparatively, 58.1% of Oxford Biomedica shares are held by institutional investors. 8.1% of Bioventix shares are held by insiders. Comparatively, 16.2% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Oxford Biomedica has a consensus price target of GBX 498.75, suggesting a potential upside of 58.33%. Given Bioventix's higher possible upside, analysts clearly believe Oxford Biomedica is more favorable than Bioventix.
Bioventix has a net margin of 63.73% compared to Bioventix's net margin of -51.78%. Oxford Biomedica's return on equity of 79.14% beat Bioventix's return on equity.
Summary
Bioventix beats Oxford Biomedica on 10 of the 17 factors compared between the two stocks.
Get Oxford Biomedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford Biomedica Competitors List
Related Companies and Tools
